GSK Offers Price Freeze On Ventolin HFA In Bid For Early Phase-Out Of CFCs
Executive Summary
GlaxoSmithKline has offered to freeze the wholesale price of its Ventolin HFA inhaler as part of its case for FDA to phase out chlorofluorocarbon albuterol metered-dose inhalers by December 31, 2005
You may also be interested in...
Albuterol HFAs Could Face Generic Competition By 2010, FDA Final Rule Says
Branded hydrofluoroalkane albuterol products may have as little as one year between the withdrawal of CFC-containing inhalers and the entry of HFA generics, according to FDA's analysis
Albuterol HFAs Could Face Generic Competition By 2010, FDA Final Rule Says
Branded hydrofluoroalkane albuterol products may have as little as one year between the withdrawal of CFC-containing inhalers and the entry of HFA generics, according to FDA's analysis
Albuterol Transition To CFC-Free: Increased Cost Could Affect Patient Access
Increases in cost of albuterol inhalers due to the transition from chlorofluorocarbons to non-ozone depleting substances could affect patient access, members of FDA's Pulmonary-Allergy Drugs Advisory Committee suggested